Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
LYRA

LYRA - Lyra Therapeutics Inc Stock Price, Fair Value and News

$2.05+0.35 (+20.59%)
Market Closed

1/100

LYRA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

1/100

LYRA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.64

Target 3M

$1.84

Target 6M

$1.74

LYRA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LYRA Price Action

Last 7 days

-8.9%

Last 30 days

-39.9%

Last 90 days

-62.9%

Trailing 12 Months

-77.6%

LYRA RSI Chart

LYRA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LYRA Valuation

Market Cap

3.6M

Price/Earnings (Trailing)

-0.11

Price/Sales (Trailing)

6.06

EV/EBITDA

0.57

Price/Free Cashflow

-0.19

LYRA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.64

Target 3M

$1.84

Target 6M

$1.74

LYRA Fundamentals

LYRA Revenue

Revenue (TTM)

600.0K

Rev. Growth (Yr)

-87.18%

Rev. Growth (Qtr)

-86.34%

LYRA Earnings

Earnings (TTM)

-32.9M

Earnings Growth (Yr)

49.6%

Earnings Growth (Qtr)

19.54%

LYRA Profitability

EBT Margin

-5488.67%

Return on Equity

761.25%

Return on Assets

-75.38%

Free Cashflow Yield

-513.88%

LYRA Investor Care

Shares Dilution (1Y)

35.57%

Diluted EPS (TTM)

-23.5

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20251.2M770.0K600.0K0
20241.7M1.8M1.5M1.5M
20231.3M1.2M1.4M1.6M
2022554.5K824.0K1.1M1.4M
2021000285.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Lyra Therapeutics Inc

LYRA
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
 CEO
 WEBSITEhttps://lyratherapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES73

Lyra Therapeutics Inc Frequently Asked Questions

LYRA is the stock ticker symbol of Lyra Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Lyra Therapeutics Inc is 3.64 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check LYRA's fair value in chart for subscribers.

The fair value guage provides a quick view whether LYRA is over valued or under valued. Whether Lyra Therapeutics Inc is cheap or expensive depends on the assumptions which impact Lyra Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LYRA.

As of Wed Jan 28 2026, LYRA's PE ratio (Price to Earnings) is -0.11 and Price to Sales (PS) ratio is 6.06. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LYRA PE ratio will change depending on the future growth rate expectations of investors.